Skip to content

Immunic

3 viewers · 30d

Total raised

$200.0M

+$200.0M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $200.0M
ROUNDS
1
INVESTORS
43
FOUNDED
N/A
HQ
New York, NY
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Immunic, Inc. is a late-stage clinical biotechnology company focused on developing novel oral therapies for chronic inflammatory, autoimmune, neurologic, and gastrointestinal diseases. The company's primary focus is on its lead drug candidate, vidofludimus calcium, which is in Phase 3 trials for the treatment of multiple sclerosis. Immunic aims to address unmet needs by targeting mechanisms like Nurr1 activation and DHODH inhibition to offer neuroprotective and anti-inflammatory benefits.

What sets it apart

The company's lead candidate, vidofludimus calcium, is a first-in-class Nurr1 activator with a multi-mechanism profile, offering neuroprotective, anti-inflammatory, and antiviral effects. This dual-action approach is designed to address neurodegeneration in multiple sclerosis, a key aspect not fully covered by many existing inflammation-focused therapies.

Funding history

1 round
Equity+2Feb 17, 2026
Form D
+$200.0M$200.0M total

Latest SEC filings

via EDGAR · CIK 0001280776
Form D · Feb 17, 2026View on EDGAR

Products

1 tracked

Vidofludimus calcium (IMU-838)

Oral Neurologic Therapy

Vidofludimus calcium is the company's lead oral drug candidate, currently in Phase 3 (ENSURE-1 and ENSURE-2) clinical trials for the treatment of relapsing multiple sclerosis (RMS). It has also demonstrated positive activity in Phase 2 trials for progressive MS and ulcerative colitis. The company plans to initiate a Phase 3 trial for primary progressive multiple sclerosis (PPMS) in 2026.

  • Oral administration
  • Acts as a Nurr1 activator, providing neuroprotective effects
  • Functions as a DHODH inhibitor, delivering anti-inflammatory and antiviral activity
  • Favorable safety profile demonstrated in previous trials

Links

WebsiteSEC EDGAR filings